Medical Developments International
Medical Developments International (MVP) is a pharmaceutical company focused on developing and distributing innovative medical devices. They operate in the acute pain and respiratory illness treatment sectors, aiming to improve patient care globally. MDI partners with organizations like CSIRO to drive industry-leading product development.
Short position
Medical Developments International (ASX:MVP) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 152 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 3.86% in September 2021. MVP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Medical Developments International (MVP) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $42.6MT (source: Derived: trailing 12 months at year end)vs $39.1M (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- NPAT
- $626.0KT (source: Derived: trailing 12 months at year end)vs $94.0K (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- EPS (diluted)
- $0.005vs $0.001 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +9.0%FY
- EPS YoY
- +488.9%FY
- Derived: trailing 12 months at year end
Summary of Annual Report 2026, 9 Oct 2026
Medical Developments International reported FY26 revenue of $42.6 million, up 9% on the prior year, and net profit after tax of $0.6 million, up from $0.1 million. No dividend was declared. The company expects higher in-market Penthrox demand in FY27, stable Respiratory segment demand, and non-recurrence of FY26 inventory stocking benefits.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- 72.1%
- Operating margin
- 2.5%
- Net margin
- 1.5%
- FCF margin
- 11.6%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- 7.92×
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- 16.3×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- 78.3×
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $42.6MT (source: Derived: trailing 12 months at year end) | $39.1M | $33.1M | $32.2M |
| Gross profit | $30.7MT (source: Derived: trailing 12 months at year end) | $29.4M | $24.4M | $22.0M |
| Operating income | $1.1MT (source: Derived: trailing 12 months at year end) | −$1.8M | −$16.9M | −$20.4M |
| EBITDA | $3.3MT (source: Derived: trailing 12 months at year end) | $3.4M | −$29.4M | −$4.3M |
| EBIT | $569.0KT (source: Derived: trailing 12 months at year end) | $243.0K | −$32.8M | −$7.4M |
| Interest expense | $65.0KT (source: Derived: trailing 12 months at year end) | $75.0K | $86.0K | $95.0K |
| Pretax income | $504.0KT (source: Derived: trailing 12 months at year end) | $168.0K | −$32.9M | −$7.5M |
| Tax | −$122.0KT (source: Derived: trailing 12 months at year end) | $74.0K | $8.1M | −$1.9M |
| NPAT | $626.0KT (source: Derived: trailing 12 months at year end) | $94.0K | −$41.0M | −$5.6M |
| Net interest income | $352.0KT (source: Derived: trailing 12 months at year end) | $302.0K | $316.0K | $562.0K |
| EPS basic | $0.006 | $0.001 | −$0.46 | −$0.065 |
| EPS diluted | $0.005 | $0.001 | −$0.46 | −$0.065 |
| Shares | n/a | 112.7M | 88.6M | 88.6M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Annual Report 2026Annual Report9 Oct 2026via asx_announcements
- FY26 Full Year ResultsFull Year Results20 Aug 2026via asx_announcements
- FY26 Full year Results Investor PresentationFull Year Results20 Aug 2026via asx_announcements
- MVP Announces FY26 Full Year ResultsFull Year Results20 Aug 2026via asx_announcements
- FY26 Full Year Results Announcement DetailsFull Year Results12 Aug 2026via asx_announcements
- Appendix 4C and Quarterly Activity Report 30 June 2026Quarterly Report24 Jul 2026via asx_announcements
- Appendix 4C and Quarterly Activity Report 31 March 2026Quarterly Report24 Apr 2026via asx_announcements
- FY26 Half Year AnnouncementHalf Year Results19 Feb 2026via asx_announcements
- FY26 Half Year PresentationHalf Year Results19 Feb 2026via asx_announcements
- FY26 Half Year Report (including Appendix 4D)Half Year Results19 Feb 2026via asx_announcements
Showing 10 of 43 reports